PACB
Pacific Biosciences of California
1.60$
+12.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 94.6% | 84.3% | 79.1% | 70.5% | 77.3% | 54.8% | 85.9% | 54.9% | 48.2% | 42.5% | 39.3% | 47.8% | |
| 29.3% | 62.8% | 12.2% | 43.6% | 11.1% | 20.0% | 19.7% | 23.0% | 18.4% | 10.3% | 4.4% | 8.1% | |
| 81.4% | 62.8% | 52.2% | 43.6% | 60.1% | 33.2% | 77.0% | 52.0% | 43.7% | 36.2% | 30.9% | 35.6% | |
| 2.7% | 4.0% | 8.3% | 9.3% | 5.0% | 10.3% | 4.1% | 1.2% | 1.1% | 2.1% | 2.2% | 4.5% | |
| 9.1% | 8.4% | 11.3% | 16.0% | 10.5% | 9.0% | 3.4% | 1.2% | 2.9% | 3.2% | 4.7% | 6.3% | |
| 5.3% | 6.5% | 10.6% | 26.3% | 20.0% | 20.3% | 6.0% | 3.9% | 4.6% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | 0.0% | 20.4% | 23.2% | 26.5% | 25.2% | 40.5% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | 20.5% | 23.2% | 26.2% | 30.9% | 1.9% | |
| 55.9% | 43.9% | 38.6% | 40.2% | 33.0% | 62.9% | 19.0% | 60.6% | 68.1% | 59.8% | 59.8% | 99.3% | |
| 25.3% | 16.7% | 24.5% | 15.5% | 11.9% | 33.2% | 9.3% | 3.6% | 14.9% | 5.4% | 5.3% | 6.9% | |
| 9.2% | 1.6% | 12.0% | 4.4% | 3.7% | 13.3% | 1.0% | 0.5% | 0.6% | 0.6% | 0.8% | 0.1% | |
| 4.5% | 3.6% | 6.1% | 6.3% | 4.0% | 5.7% | 0.9% | 0.5% | 0.7% | 0.9% | 1.3% | 2.6% | |
| 11.3% | 11.4% | 11.7% | 9.5% | 8.6% | 10.7% | – | 44.6% | 50.7% | 51.1% | 51.4% | 82.3% | |
| 44.1% | 56.1% | 61.4% | 59.8% | 67.0% | 37.1% | 81.0% | 39.4% | 31.9% | 40.2% | 40.2% | 0.7% | |
| -547.3% | -544.0% | -571.2% | -610.6% | -576.8% | -720.5% | -250.5% | -60.7% | -86.7% | -105.3% | -170.5% | -343.8% | |
| 56.6% | 57.7% | 64.7% | 73.3% | 79.3% | 103.1% | 42.3% | 10.2% | 12.7% | 14.5% | 22.9% | 38.3% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.